Navetta offers an innovative solution for safety testing of drugs and particles at the Air-Liquid Interface.
What makes Navetta different?
This novel exposure system uses smooth, low-speed horizontal airflow combined with an electrical field that enhances particle deposition directly onto lung cells. Temperature and humidity remain controlled, keeping cells viable throughout exposure.
Key advantages:
-
High deposition efficiency – Charged particles are accelerated toward cells via an electric field, dramatically increasing deposition rates
-
Uniform distribution – Homogeneous electric field ensures even particle coverage across the exposure area
-
Ultrafine & nanoparticle ready – Strong electrostatic forces capture the smallest particles that would otherwise remain suspended
-
Seamless integration – Successfully couples with Preciseinhale® for DPI/MDI testing and PowderX for accurate delivery of the smallest particle amounts
The science behind it:
Navetta uses electrostatic deposition to actively direct aerosol particles onto cell cultures grown at the Air-Liquid Interface (ALI) – a game-changer for precision testing.
This breakthrough stems from an outstanding collaboration between VITO (Belgium) and the Department of Biosciences and Medical Biology – University of Salzburg. The system's precision and reliability were recently highlighted in the Computational and Structural Biotechnology Journal.
Read the publication.
The commercial version of Navetta is now available through VITROCELL Navetta.
Special recognition goes to Evelien Frijns, Sandra Verstraelen, Jo van Laer (VITO), and Martin Himly (PLUS) for making this innovation possible.
What's your take on this advancement in safety testing?